Literature DB >> 15562496

In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent.

Clifford R Jack1, Michael Garwood, Thomas M Wengenack, Bret Borowski, Geoffrey L Curran, Joseph Lin, Gregor Adriany, Olli H J Gröhn, Roger Grimm, Joseph F Poduslo.   

Abstract

One of the cardinal pathologic features of Alzheimer's disease (AD) is the formation of senile, or amyloid, plaques. Transgenic mice have been developed that express one or more of the genes responsible for familial AD in humans. Doubly transgenic mice develop "human-like" plaques, providing a mechanism to study amyloid plaque biology in a controlled manner. Imaging of labeled plaques has been accomplished with other modalities, but only MRI has sufficient spatial and contrast resolution to visualize individual plaques noninvasively. Methods to optimize visualization of plaques in vivo in transgenic mice at 9.4 T using a spin echo sequence based on adiabatic pulses are described. Preliminary results indicate that a spin echo acquisition more accurately reflects plaque size, while a T2* weighted gradient echo sequence reflects plaque iron content, not plaque size. In vivo MRI-ex vivo MRI-in vitro histologic correlations are provided. Histologically verified plaques as small as 50 microm in diameter were visualized in living animals. To our knowledge this work represents the first demonstration of noninvasive in vivo visualization of individual AD plaques without the use of a contrast agent.

Entities:  

Mesh:

Year:  2004        PMID: 15562496      PMCID: PMC2744889          DOI: 10.1002/mrm.20266

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  26 in total

1.  Adaptive technique for high-definition MR imaging of moving structures.

Authors:  R L Ehman; J P Felmlee
Journal:  Radiology       Date:  1989-10       Impact factor: 11.105

2.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

Authors:  D A Evans; H H Funkenstein; M S Albert; P A Scherr; N R Cook; M J Chown; L E Hebert; C H Hennekens; J O Taylor
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

3.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.

Authors:  Brian J Bacskai; Gregory A Hickey; Jesse Skoch; Stephen T Kajdasz; Yanming Wang; Guo-Feng Huang; Chester A Mathis; William E Klunk; Bradley T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-29       Impact factor: 11.205

4.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

5.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

Authors:  Joseph F Poduslo; Geoffry L Curran; Jane A Peterson; Daniel J McCormick; Abdul H Fauq; Murad A Khan; Thomas M Wengenack
Journal:  Biochemistry       Date:  2004-05-25       Impact factor: 3.162

6.  Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging.

Authors:  Jiangyang Zhang; Paul Yarowsky; Marcia N Gordon; Giovanni Di Carlo; Sanjay Munireddy; Peter C M van Zijl; Susumu Mori
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

7.  Fast anatomical imaging of the heart and assessment of myocardial perfusion with arrhythmia insensitive magnetization preparation.

Authors:  N V Tsekos; Y Zhang; H Merkle; N Wilke; M Jerosch-Herold; A Stillman; K Uğurbil
Journal:  Magn Reson Med       Date:  1995-10       Impact factor: 4.668

8.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

9.  MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Joseph A Helpern; Sang-Pil Lee; Maria F Falangola; Victor V Dyakin; Adam Bogart; Babak Ardekani; Karen Duff; Craig Branch; Thomas Wisniewski; Mony J de Leon; Oliver Wolf; Jacqueline O'Shea; Ralph A Nixon
Journal:  Magn Reson Med       Date:  2004-04       Impact factor: 4.668

10.  The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

Authors:  William E Klunk; Yanming Wang; Guo-feng Huang; Manik L Debnath; Daniel P Holt; Li Shao; Ronald L Hamilton; Milos D Ikonomovic; Steven T DeKosky; Chester A Mathis
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

View more
  66 in total

1.  Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain.

Authors:  T M Wengenack; D A Reyes; G L Curran; B J Borowski; J Lin; G M Preboske; S S Holasek; E J Gilles; R Chamberlain; M Marjanska; C R Jack; M Garwood; J F Poduslo
Journal:  Neuroimage       Date:  2010-08-20       Impact factor: 6.556

2.  Neuroimaging: anything to do with neurotherapeutics?

Authors:  Jose C Masdeu; Rohit Bakshi
Journal:  NeuroRx       Date:  2005-04

3.  Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease.

Authors:  Ryan Chamberlain; Thomas M Wengenack; Joseph F Poduslo; Michael Garwood; Clifford R Jack
Journal:  Curr Med Imaging Rev       Date:  2011-02

4.  Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques.

Authors:  André F Martins; Jean-François Morfin; Carlos F G C Geraldes; Eva Tóth
Journal:  J Biol Inorg Chem       Date:  2013-12-03       Impact factor: 3.358

Review 5.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

6.  Hydration profiles of amyloidogenic molecular structures.

Authors:  Florin Despa; Ariel Fernández; L Ridgway Scott; R Stephen Berry
Journal:  J Biol Phys       Date:  2008-11-05       Impact factor: 1.365

7.  Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.

Authors:  Muthu Ramakrishnan; Thomas M Wengenack; Karunya K Kandimalla; Geoffry L Curran; Emily J Gilles; Marina Ramirez-Alvarado; Joseph Lin; Michael Garwood; Clifford R Jack; Joseph F Poduslo
Journal:  Pharm Res       Date:  2008-04-29       Impact factor: 4.200

8.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

9.  SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.

Authors:  Laurel O Sillerud; Nathan O Solberg; Ryan Chamberlain; Robert A Orlando; John E Heidrich; David C Brown; Christina I Brady; Thomas A Vander Jagt; Michael Garwood; David L Vander Jagt
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.